LB Pharmaceuticals Inc.
6 clinical trials · Sponsor
◉ Watch LB Pharmaceuticals Inc.
| Record | Firm | Date |
|---|---|---|
| 52-week Open Label Safety-Tolerability Study (NCT07369154) | LB Pharmaceuticals Inc. | 2026-04-23 |
| Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia (NCT07363577) | LB Pharmaceuticals Inc. | 2026-03-25 |
| Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. (NCT07494305) | LB Pharmaceuticals Inc. | 2026-01-23 |
| Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia (NCT06179108) | LB Pharmaceuticals Inc. | 2023-11-29 |
| Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers (NCT04588129) | LB Pharmaceuticals Inc. | 2021-01-05 |
| Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults (NCT04187560) | LB Pharmaceuticals Inc. | 2020-01-22 |
Track LB Pharmaceuticals Inc. automatically
Every clearance here is in the API, with alerts when new ones post.